Phase I study of ONO-7268MX2

A Phase I study of ONO-7268MX2 in patients with hepatocellular carcinoma

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222427

Enrollment

Registered

2014-03-18

Start date

2014-03-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

investigational material(s) Generic name etc : ONO-7268MX2 INN of investigational material : Therapeutic category code : 631 Vaccines Dosage and Administration for Investigational material : Subcutan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have the history of histologically, cytologically or clinically confirmed hepatocellular carcinoma 2. Advanced hepatocellular carcinoma patients with no standard or adequate therapeutic options 3. Life expectancy of at least 3 months

Exclusion criteria

Exclusion criteria: 1. Patients with severe complication 2. Patients with multiple primary cancers

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Efficacy, Pharmacological action	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026